Molecular Analysis of Retinoblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

41 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-04-30

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Retinoblastoma is a childhood tumor of the retina that affects approximately 1 in 18,000 children. Retinoblastoma is more prevalent in Central America, where most patients present with advanced intraocular and extraocular disease. Therefore, we have formed collaboration with Central American investigators to provide us with frozen retinoblastoma tumors from patients undergoing routine enucleation. The objective of this protocol is to begin to identify the mutations and gene expression changes that occur in retinoblastoma cells following RB1 gene inactivation in order to more effectively target chemotherapy for treating bilateral retinoblastoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imaging and Evolution of Pigmented Tumors of the Anterior Ocular System in Children

NCT07120178

Pigmented Tumours of the Anterior Ocular System in Children

RECRUITING

Research on the Environment and Children's Health: Retinoblastoma

NCT00582049

Retinoblastoma

COMPLETED

Evaluation of MRI of the Pineal Gland in Retinoblastoma

NCT06367569

Retinoblastoma

COMPLETED

Role of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Children With Myocarditis

NCT00693134

Myocarditis

COMPLETED

Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma

NCT04425434

Retinoblastoma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a biology protocol with no treatment regimen associated. Following routine enucleation of the retinoblastoma affected eye, a portion of the tumor will be removed and flash frozen and sent to St. Jude for RNA and DNA analysis. Some tissue will undergo histopathological analysis and tissue microarrays will be isolated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinoblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Retinoblastoma

Tissue samples taken from retinoblastoma

Intervention Type OTHER

Tissue banking

5 ml peripheral blood

Intervention Type OTHER

White blood cells will be isolated from the blood sample as a source of genomic DNA.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tissue samples taken from retinoblastoma

Tissue banking

Intervention Type OTHER

5 ml peripheral blood

White blood cells will be isolated from the blood sample as a source of genomic DNA.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have clinical diagnosis of retinoblastoma (to be confirmed histologically after enucleation)
* Legal guardians must willing to sign an informed consent indicating that they are aware of this study and its possible benefits. Legal guardians will be given a copy of the consent form.
* Patient is being seen at this AHOPCA institution:

Exclusion Criteria

* Ophthalmologist or oncologist is concerned that sampling will interfere with staging.
* Diagnosis other than retinoblastoma.
* Affiliated hospital is unable to provide pathologic evidence of retinoblastoma.

Eligible Sex

ALL

Accepts Healthy Volunteers

No